Previous Close | 12.41 |
Open | 12.30 |
Bid | 11.55 x 1400 |
Ask | 11.70 x 900 |
Day's Range | 12.10 - 12.52 |
52 Week Range | 6.08 - 14.00 |
Volume | |
Avg. Volume | 36,116 |
Market Cap | 78.698M |
Beta (5Y Monthly) | 1.26 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -30.20 |
Earnings Date | Mar 29, 2024 - Apr 02, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 36.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for TIL
Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.
DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced a strategic update. Instil has entered into an agreement with a collaborator that has a successful track record of manufacturing and dosing patients with cell therapies to conduct preclinical manufacturing feasibility studies
DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that a 1-for-20 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m. Eastern Time on Thursday, December 7, 2023. The Company’s common stock will begin trading on a reverse stock spli